VAPITADINE DIHYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H20N4O.2ClH
Molecular Weight	369.289
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.Cl.NC(=O)C1=CN=C2N1CCC3=C(C=CC=C3)C24CCNCC4

InChI

InChIKey=BOYLPLUVCXUHDJ-UHFFFAOYSA-N

InChI=1S/C17H20N4O.2ClH/c18-15(22)14-11-20-16-17(6-8-19-9-7-17)13-4-2-1-3-12(13)5-10-21(14)16;;/h1-4,11,19H,5-10H2,(H2,18,22);2*1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C17H20N4O
Molecular Weight	296.3669
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://adisinsight.springer.com/drugs/800020866 | https://www.drugbank.ca/drugs/DB05738 | http://media.corporate-ir.net/media_files/irol/14/142048/scientific_pubs/BRTXPostervapitadininADAAD2008Final.pdf | https://www.pharmacodia.com/yaodu/html/v1/chemicals/d6d83fd1acd1918a677906afc9bdc1d7.html

Vapitadine (R129160; Hivenyl™) is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis. Vapitadine is a new selective, non-sedative H1antihistamine. In several in vitro and in vivo pharmacological models, vapitadine is at least as potent as cetirizine (Zyrtec®) and does not penetrate the blood-brain barrier. An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses. Vapitadine had been in phase II clinical trials for the treatment of patients with atopic dermatitis. However, no development has been reported.

CNS Activity

Originator

Approval Year

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

In healthy volunteers vapitadine dose-dependently inhibits the histamine-induced wheal and flare reaction. Vapitadine shows a fast onset of action (within 1 hour) as well as a long-lasting (>24 hours) antihistaminic activity (from 10 mg onwards). Vapitadine does not induce sedation up to the highest dose tested (150 mg o.d. for 8 days). After a one-week run-in period, 43 adult patients with atopic dermatitis were randomized to treatment with oral vapitadine 60 mg twice daily (n=22) or placebo (n=21) for one week.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:04:14 GMT 2023` Edited by `admin` on `Fri Dec 15 16:04:14 GMT 2023`
Record UNII	R612XR8A9F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VAPITADINE DIHYDROCHLORIDE

Official Name

English

VAPITADINE DIHYDROCHLORIDE [USAN]

Common Name

English

R-129160

Code

English

Vapitadine dihydrochloride [WHO-DD]

Common Name

English

R129160

Code

English

5,6-DIHYDROSPIRO(11H-IMIDAZO(2,1-B)(3)BENZAZEPINE-11,4'-PIPERIDINE)-3-CARBOXAMIDE DIHYDROCHLORIDE

Systematic Name

English

SPIRO(11H-IMIDAZO(2,1-B)(3)BENZAZEPINE-11,4'-PIPERIDINE)-3-CARBOXAMIDE, 5,6-DIHYDRO-, DIHYDROCHLORIDE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29578